Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) – Analysts at HC Wainwright upped their FY2023 earnings estimates for Aclaris Therapeutics in a report released on Monday, January 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($1.65) per share for the year, up from their previous forecast of […]
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) was downgraded by research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued to investors on Monday, Marketbeat Ratings reports. A number of other equities research analysts also recently weighed in on the company. William Blair downgraded Aclaris Therapeutics from […]
By Sabela Ojea Shares of Aclaris Therapeutics on Wednesday dropped 12% to $1.13 in after-hours trading after the company said it received not statistically.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective […]
Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average […]